Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Broadly Neutralizing Antibodies for HIV-1 Prevention
Stephen R. Walsh, Michael S. Seaman
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Human Antibodies for Viral Infections
James E. Crowe
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 349-386
Closed Access | Times Cited: 37
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
Nonhlanhla N. Mkhize, Anna Yssel, Haajira Kaldine, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 6, pp. e1011469-e1011469
Open Access | Times Cited: 23
Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
Mohammad Ullah Nayan, Brady Sillman, Mahmudul Hasan, et al.
Advanced Drug Delivery Reviews (2023) Vol. 200, pp. 115009-115009
Open Access | Times Cited: 22
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Michal Juraska, Hongjun Bai, Allan C. deCamp, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 4
Open Access | Times Cited: 8
Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges
Vivek Agrahari, Sharon M. Anderson, M. Melissa Peet, et al.
Expert Opinion on Drug Delivery (2022) Vol. 19, Iss. 10, pp. 1365-1380
Open Access | Times Cited: 33
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E. Sobieszczyk, Sharon Mannheimer, Carmen A. Paez, et al.
The Lancet HIV (2023) Vol. 10, Iss. 10, pp. e653-e662
Open Access | Times Cited: 18
Immunization with germ line–targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques
Ashley N. Nelson, Xiaoying Shen, Sravani Vekatayogi, et al.
Science Immunology (2024) Vol. 9, Iss. 98
Closed Access | Times Cited: 6
The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter
Miruna-Maria Apetroaei, Bruno Ștefan Velescu, Marina Ionela Nedea, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 915-915
Open Access | Times Cited: 5
Meeting summary: Global vaccine and immunization research forum, 2023
Birgitte Giersing, Annie X. Mo, Angela Hwang, et al.
Vaccine (2025) Vol. 46, pp. 126686-126686
Open Access
Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes
Harry B. Gristick, Harald Hartweger, Yoshiaki Nishimura, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance
Paula Marantz Cohen, Bronwen E. Lambson, Nonhlanhla N. Mkhize, et al.
Journal of Virology (2025)
Open Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro Dianah Chawana, Stephen R. Walsh, Lynda Stranix‐Chibanda, et al.
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection
Myra Happe, Rebecca M. Lynch, Carl J. Fichtenbaum, et al.
JCI Insight (2025) Vol. 10, Iss. 4
Open Access
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage
Kshitij Wagh, Michael S. Seaman
Current Opinion in HIV and AIDS (2023) Vol. 18, Iss. 4, pp. 164-170
Open Access | Times Cited: 13
Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Yuxiang Zhao, Linchuan Gan, Dangjin Ke, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 13
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Sharana Mahomed
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 4
Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains
Shixia Wang, Kun‐Wei Chan, Danlan Wei, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
Sharana Mahomed, Nigel Garrett, Edmund V. Capparelli, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 3, pp. 510-520
Open Access | Times Cited: 21
Monoclonal antibodies for malaria prevention
Maya Aleshnick, Melina Florez-Cuadros, Thomas Martinson, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1810-1821
Open Access | Times Cited: 19
Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy
Sarah Dohadwala, Matthew T. Geib, Joseph A. Politch, et al.
Frontiers in Reproductive Health (2024) Vol. 5
Open Access | Times Cited: 3
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
Stephen R. Walsh, Cynthia L. Gay, Shelly Karuna, et al.
PLoS Medicine (2024) Vol. 21, Iss. 6, pp. e1004329-e1004329
Open Access | Times Cited: 3
Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein
C. Garrett Rappazzo, Ching‐Lin Hsieh, Scott A. Rush, et al.
Immunity (2022) Vol. 55, Iss. 9, pp. 1710-1724.e8
Open Access | Times Cited: 16
Construction and Applications of Mammalian Cell-Based DNA-Encoded Peptide/Protein Libraries
Yi Wang, Kaili Zhang, Yanjie Zhao, et al.
ACS Synthetic Biology (2023) Vol. 12, Iss. 7, pp. 1874-1888
Closed Access | Times Cited: 9
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
Seemal F. Awan, Myra Happe, Amelia R. Hofstetter, et al.
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 4, pp. 247-257
Closed Access | Times Cited: 15
A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin
Eirini Vamva, Stosh Ozog, Daniel P. Leaman, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 28, pp. 366-384
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top